A citation-based method for searching scientific literature

Matthew Bott, Marie Brevet, Barry S Taylor, Shigeki Shimizu, Tatsuo Ito, Lu Wang, Jenette Creaney, Richard A Lake, Maureen F Zakowski, Boris Reva, Chris Sander, Robert Delsite, Simon Powell, Qin Zhou, Ronglai Shen, Adam Olshen, Valerie Rusch, Marc Ladanyi. Nat Genet 2011
Times Cited: 461







List of co-cited articles
774 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Germline BAP1 mutations predispose to malignant mesothelioma.
Joseph R Testa, Mitchell Cheung, Jianming Pei, Jennifer E Below, Yinfei Tan, Eleonora Sementino, Nancy J Cox, A Umran Dogan, Harvey I Pass, Sandra Trusa,[...]. Nat Genet 2011
634
44

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
Raphael Bueno, Eric W Stawiski, Leonard D Goldstein, Steffen Durinck, Assunta De Rienzo, Zora Modrusan, Florian Gnad, Thong T Nguyen, Bijay S Jaiswal, Lucian R Chirieac,[...]. Nat Genet 2016
455
44

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Julija Hmeljak, Francisco Sanchez-Vega, Katherine A Hoadley, Juliann Shih, Chip Stewart, David Heiman, Patrick Tarpey, Ludmila Danilova, Esther Drill, Ewan A Gibb,[...]. Cancer Discov 2018
258
44

High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Masaki Nasu, Mitsuru Emi, Sandra Pastorino, Mika Tanji, Amy Powers, Hugh Luk, Francine Baumann, Yu-An Zhang, Adi Gazdar, Shreya Kanodia,[...]. J Thorac Oncol 2015
189
29

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo, Juliann Chmielecki, Chandra Goparaju, Adriana Heguy, Igor Dolgalev, Michele Carbone, Sara Seepo, Matthew Meyerson, Harvey I Pass. Cancer Res 2015
196
24

Frequent mutation of BAP1 in metastasizing uveal melanomas.
J William Harbour, Michael D Onken, Elisha D O Roberson, Shenghui Duan, Li Cao, Lori A Worley, M Laurin Council, Katie A Matatall, Cynthia Helms, Anne M Bowcock. Science 2010
894
24

BAP1 and cancer.
Michele Carbone, Haining Yang, Harvey I Pass, Thomas Krausz, Joseph R Testa, Giovanni Gaudino. Nat Rev Cancer 2013
388
24

BAP1 loss defines a new class of renal cell carcinoma.
Samuel Peña-Llopis, Silvia Vega-Rubín-de-Celis, Arnold Liao, Nan Leng, Andrea Pavía-Jiménez, Shanshan Wang, Toshinari Yamasaki, Leah Zhrebker, Sharanya Sivanand, Patrick Spence,[...]. Nat Genet 2012
604
23

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold,[...]. J Clin Oncol 2003
19

Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB.
Johanna C Scheuermann, Andrés Gaytán de Ayala Alonso, Katarzyna Oktaba, Nga Ly-Hartig, Robert K McGinty, Sven Fraterman, Matthias Wilm, Tom W Muir, Jürg Müller. Nature 2010
506
19

Germline mutations in BAP1 predispose to melanocytic tumors.
Thomas Wiesner, Anna C Obenauf, Rajmohan Murali, Isabella Fried, Klaus G Griewank, Peter Ulz, Christian Windpassinger, Werner Wackernagel, Shea Loy, Ingrid Wolf,[...]. Nat Genet 2011
467
17

Loss of BAP1 function leads to EZH2-dependent transformation.
Lindsay M LaFave, Wendy Béguelin, Richard Koche, Matt Teater, Barbara Spitzer, Alan Chramiec, Efthymia Papalexi, Matthew D Keller, Todd Hricik, Katerina Konstantinoff,[...]. Nat Med 2015
208
17

BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.
D E Jensen, M Proctor, S T Marquis, H P Gardner, S I Ha, L A Chodosh, A M Ishov, N Tommerup, H Vissing, Y Sekido,[...]. Oncogene 1998
512
16

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Marta Cigognetti, Silvia Lonardi, Simona Fisogni, Piera Balzarini, Vilma Pellegrini, Andrea Tironi, Luisa Bercich, Mattia Bugatti, Giulio Rossi, Bruno Murer,[...]. Mod Pathol 2015
152
16

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia,[...]. Lancet 2021
232
16

Novel insights into mesothelioma biology and implications for therapy.
Timothy A Yap, Joachim G Aerts, Sanjay Popat, Dean A Fennell. Nat Rev Cancer 2017
186
15

Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Marco Lo Iacono, Valentina Monica, Luisella Righi, Federica Grosso, Roberta Libener, Simona Vatrano, Paolo Bironzo, Silvia Novello, Loredana Musmeci, Marco Volante,[...]. J Thorac Oncol 2015
98
15

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Gérard Zalcman, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant,[...]. Lancet 2016
503
14

Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.
Helen Yu, Helen Pak, Ian Hammond-Martel, Mehdi Ghram, Amélie Rodrigue, Salima Daou, Haithem Barbour, Luc Corbeil, Josée Hébert, Elliot Drobetsky,[...]. Proc Natl Acad Sci U S A 2014
217
14

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.
Angela Bononi, Carlotta Giorgi, Simone Patergnani, David Larson, Kaitlyn Verbruggen, Mika Tanji, Laura Pellegrini, Valentina Signorato, Federica Olivetto, Sandra Pastorino,[...]. Nature 2017
206
14

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Tomoyuki Hida, Makoto Hamasaki, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Akinori Iwasaki, Tatsuro Okamoto, Yoshinao Oda, Hiroshi Honda,[...]. Lung Cancer 2017
84
15

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Michele Carbone, Prasad S Adusumilli, H Richard Alexander, Paul Baas, Fabrizio Bardelli, Angela Bononi, Raphael Bueno, Emanuela Felley-Bosco, Francoise Galateau-Salle, David Jablons,[...]. CA Cancer J Clin 2019
156
13

BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.
Brandon S Sheffield, Harry C Hwang, Anna F Lee, Kim Thompson, Stephanie Rodriguez, Christopher H Tse, Allen M Gown, Andrew Churg. Am J Surg Pathol 2015
112
12

BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Karen H Ventii, Narra S Devi, Kenneth L Friedrich, Tatiana A Chernova, Mourad Tighiouart, Erwin G Van Meir, Keith D Wilkinson. Cancer Res 2008
234
12

Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma.
Yoshie Yoshikawa, Ayuko Sato, Tohru Tsujimura, Mitsuru Emi, Tomonori Morinaga, Kazuya Fukuoka, Shusai Yamada, Aki Murakami, Nobuyuki Kondo, Seiji Matsumoto,[...]. Cancer Sci 2012
124
12

Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Raffit Hassan, Betsy Morrow, Anish Thomas, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Meghana Gadiraju, Vasiliki Panou, Shaojian Gao, Idrees Mian,[...]. Proc Natl Acad Sci U S A 2019
69
17

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
Vasiliki Panou, Meghana Gadiraju, Arthur Wolin, Caroline M Weipert, Emily Skarda, Aliya N Husain, Jyoti D Patel, Buerkley Rose, Shannon R Zhang, Madison Weatherly,[...]. J Clin Oncol 2018
87
13

p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.
J Q Cheng, S C Jhanwar, W M Klein, D W Bell, W C Lee, D A Altomare, T Nobori, O I Olopade, A J Buckler, J R Testa. Cancer Res 1994
328
12


Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.
Yuchen Jiao, Timothy M Pawlik, Robert A Anders, Florin M Selaru, Mirte M Streppel, Donald J Lucas, Noushin Niknafs, Violeta Beleva Guthrie, Anirban Maitra, Pedram Argani,[...]. Nat Genet 2013
447
11

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez,[...]. Lancet Oncol 2019
228
11

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Emilie van Brummelen. Lancet Oncol 2017
299
11

Germline mutations in BAP1 impair its function in DNA double-strand break repair.
Ismail Hassan Ismail, Riley Davidson, Jean-Philippe Gagné, Zhi Zhong Xu, Guy G Poirier, Michael J Hendzel. Cancer Res 2014
125
11

Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu, Yuwaraj Kadariya, Mitchell Cheung, Jianming Pei, Jacqueline Talarchek, Eleonora Sementino, Yinfei Tan, Craig W Menges, Kathy Q Cai, Samuel Litwin,[...]. Cancer Res 2014
89
12

Genomic Landscape of Malignant Mesotheliomas.
Shumei Kato, Brett N Tomson, Timon P H Buys, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Mol Cancer Ther 2016
40
25

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Aliya Noor Husain, Thomas V Colby, Nelson G Ordóñez, Timothy Craig Allen, Richard Luther Attanoos, Mary Beth Beasley, Kelly Jo Butnor, Lucian R Chirieac, Andrew M Churg, Sanja Dacic,[...]. Arch Pathol Lab Med 2018
265
10

BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Tomoyuki Hida, Makoto Hamasaki, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Akinori Iwasaki, Tatsuro Okamoto, Yoshinao Oda, Hiroshi Honda,[...]. Pathol Int 2016
52
19

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
Simion Chiosea, Alyssa Krasinskas, Philip T Cagle, Kisha A Mitchell, Dani S Zander, Sanja Dacic. Mod Pathol 2008
139
10

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Maria J Disselhorst, Josine Quispel-Janssen, Ferry Lalezari, Kim Monkhorst, Jeltje F de Vries, Vincent van der Noort, Emmy Harms, Sjaak Burgers, Paul Baas. Lancet Respir Med 2019
124
10

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim Aerts, Susana Cedres Perez, Alessandra Bearz, Kristiaan Nackaerts, Dean A Fennell, Dariusz Kowalski, Anne S Tsao,[...]. Lancet Oncol 2017
245
10

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
Hedy L Kindler, Nofisat Ismaila, Samuel G Armato, Raphael Bueno, Mary Hesdorffer, Thierry Jahan, Clyde Michael Jones, Markku Miettinen, Harvey Pass, Andreas Rimner,[...]. J Clin Oncol 2018
202
10

BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
Danny D Sahtoe, Willem J van Dijk, Reggy Ekkebus, Huib Ovaa, Titia K Sixma. Nat Commun 2016
100
10

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
Raunak Shrestha, Noushin Nabavi, Yen-Yi Lin, Fan Mo, Shawn Anderson, Stanislav Volik, Hans H Adomat, Dong Lin, Hui Xue, Xin Dong,[...]. Genome Med 2019
51
19

Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.
Yuwaraj Kadariya, Mitchell Cheung, Jinfei Xu, Jianming Pei, Eleonora Sementino, Craig W Menges, Kathy Q Cai, Frank J Rauscher, Andres J Klein-Szanto, Joseph R Testa. Cancer Res 2016
62
16

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
A B Bianchi, S I Mitsunaga, J Q Cheng, W M Klein, S C Jhanwar, B Seizinger, N Kley, A J Klein-Szanto, J R Testa. Proc Natl Acad Sci U S A 1995
252
10


Functional inactivation of NF2/merlin in human mesothelioma.
Claudio Thurneysen, Isabelle Opitz, Stefanie Kurtz, Walter Weder, Rolf A Stahel, Emanuela Felley-Bosco. Lung Cancer 2009
95
9

The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
Francoise Galateau-Salle, Andrew Churg, Victor Roggli, William D Travis. J Thorac Oncol 2016
164
9

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Josine Quispel-Janssen, Vincent van der Noort, Jeltje F de Vries, Marion Zimmerman, Ferry Lalezari, Erik Thunnissen, Kim Monkhorst, Robert Schouten, Laurel Schunselaar, Maria Disselhorst,[...]. J Thorac Oncol 2018
138
9

BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.
Hiroyuki Nishikawa, Wenwen Wu, Ayaka Koike, Ryoko Kojima, Hiromichi Gomi, Mamoru Fukuda, Tomohiko Ohta. Cancer Res 2009
133
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.